Roberts Cai M, Cardenas Carlos, Tedja Roslyn
Obstetrics, Gynecology and Reproductive Sciences Department, Yale School of Medicine, New Haven, CT 06520, USA.
Cancers (Basel). 2019 Jul 30;11(8):1083. doi: 10.3390/cancers11081083.
Epithelial ovarian cancer is the deadliest gynecologic cancer, due in large part to recurrent tumors. Recurrences tend to have metastasized, mainly in the peritoneal cavity and developed resistance to the first line chemotherapy. Key to the progression and ultimate lethality of ovarian cancer is the existence of extensive intra-tumoral heterogeneity (ITH). In this review, we describe the genetic and epigenetic changes that have been reported to give rise to different cell populations in ovarian cancer. We also describe at length the contributions made to heterogeneity by both linear and parallel models of clonal evolution and the existence of cancer stem cells. We dissect the key biological signals from the tumor microenvironment, both directly from other cell types in the vicinity and soluble or circulating factors. Finally, we discuss the impact of tumor heterogeneity on the choice of therapeutic approaches in the clinic. Variability in ovarian tumors remains a major barrier to effective therapy, but by leveraging future research into tumor heterogeneity, we may be able to overcome this barrier and provide more effective, personalized therapy to patients.
上皮性卵巢癌是最致命的妇科癌症,很大程度上归因于复发性肿瘤。复发肿瘤往往已经发生转移,主要在腹腔内,并对一线化疗产生耐药性。卵巢癌进展和最终致死的关键在于广泛的肿瘤内异质性(ITH)的存在。在本综述中,我们描述了据报道可导致卵巢癌中不同细胞群体产生的遗传和表观遗传变化。我们还详细描述了克隆进化的线性和平行模型以及癌症干细胞的存在对异质性的贡献。我们剖析了来自肿瘤微环境的关键生物信号,这些信号既直接来自附近的其他细胞类型,也来自可溶性或循环因子。最后,我们讨论了肿瘤异质性对临床治疗方法选择的影响。卵巢肿瘤的变异性仍然是有效治疗的主要障碍,但通过利用未来对肿瘤异质性的研究,我们或许能够克服这一障碍,为患者提供更有效、个性化的治疗。